RxDoctor Payments Data

Michael Prejean, MD

Psychiatry · Lafayette, LANPI 1215087887

Payments from drug & device makers

$3,929in general payments, 2019–2025

Across 238 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • AbbVie$867
  • Otsuka America Pharmaceutical, Inc.$348
  • Johnson & Johnson$308
  • Sunovion Pharmaceuticals Inc.$302
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$226
  • plus $555 from 9 others

What the payments were for

  • Food & beverage$3,82997%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,929 in reported general payments places this provider in the 85th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$55,578
Medicare patients
125
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate130$464,550
Invega TrinzaPaliperidone Palmitate13$142,621
Abilify MaintenaAripiprazole41$113,685
AristadaAripiprazole Lauroxil27$81,010
VraylarCariprazine Hcl40$62,207
UzedyRisperidone17$54,323
CaplytaLumateperone Tosylate23$38,879
RexultiBrexpiprazole18$27,178
LybalviOlanzapine/Samidorphan Malate16$25,612
JardianceEmpagliflozin13$8,903
Clozapine97$8,496
TradjentaLinagliptin14$8,074
LinzessLinaclotide12$7,747
Pimozide13$7,692
Divalproex Sodium ErDivalproex Sodium92$7,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$308$607,171143 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$348$140,86359 claims
Alkermes, Inc.Aristada, Lybalvi$1,323$106,62143 claims
AbbVieVraylar, Linzess$867$69,95452 claims
Teva Pharmaceuticals USA, Inc.Uzedy, Loxapine$105$56,52166 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$226$38,87923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →